10-Q: BioScience Health Innovations Reports Q3 2026 Results, Faces Revenue Decline

BioScience Health Innovations Inc. reported a net loss of $149,225 for Q3 2026 and a year-to-date loss of $564,885, with revenues declining compared to the prior year, attributed to market adjustments and delayed orders.

Summary

• BioScience Health Innovations Inc. reported a net loss of $149,225 for the three months ended September 30, 2026, compared to a net loss of $8,782 for the same period in 2025.
• For the nine months ended September 30, 2026, the company reported a net loss of $564,885, a significant shift from a net income of $875,720 in the prior year.
• Revenue for the three months ended September 30, 2026, was $970,071, down from $1,131,427 in the prior year, attributed to sales channel adjustments and increased competition.
• Revenue for the nine months ended September 30, 2026, was $2,757,381, down from $4,115,960 in the prior year, with a major co-brand customer order rescheduled.
• Operating expenses increased in both periods due to preparations for a senior exchange listing, increased marketing, R&D, and accounting system upgrades.
• The company reported cash of $1,691,858 as of September 30, 2026, which management believes is sufficient to meet obligations over the next year.
• Subsequent to the quarter, the company announced plans to acquire Vital Core, Inc. and a 40% interest in a customer relationship platform from a related party.
• Material weaknesses in internal controls were identified, including a lack of sufficient accounting resources, segregation of duties, an independent board/audit committee, and documented policies.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to declining revenues, increased net losses, and material weaknesses in internal controls, despite strategic investments in technology.

Positives

• Cash balance of $1,691,858 as of September 30, 2026, which management believes is sufficient for the next year.
• Net working capital of $2,726,135 as of September 30, 2026.
• Strategic investment in MODS Max technology platform and intellectual property development.
• Subsequent event: Agreement to acquire Vital Core, Inc., a company developing hair-growth and scalp-care technologies.
• Subsequent event: Agreement to acquire a 40% ownership interest in a customer relationship platform with approximately 15,000 active customers.
• Subsequent event: Research Funding and Master Distributor Agreement with Rule Imports, LLC for $250,000 in funding.
• Progress in preparing for a potential senior exchange uplisting, including engaging an uplisting advisor and adding independent board member candidates.
• Continued development and patent applications for Methylene Blue and mitochondrial health products.

Negatives

• Net loss of $149,225 for Q3 2026, compared to a net loss of $8,782 in Q3 2025.
• Net loss of $564,885 for the nine months ended September 30, 2026, compared to a net income of $875,720 in the same period of 2025.
• Revenue decline in both the three-month and nine-month periods ended September 30, 2026, compared to 2025.
• Increased operating expenses in both periods due to strategic investments and preparations for an exchange listing.
• Material weaknesses identified in internal control over financial reporting, including insufficient accounting resources and lack of an independent audit committee.
• Significant cash used in operating activities for the nine months ended September 30, 2026 ($1,244,807).
• Delayed distribution opportunities originally expected to contribute revenue in 2026, now targeted for 2027.
• The company has not obtained an independent appraisal of its MODS Max technology.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise capital and achieve profitability.
• Material weaknesses in internal control over financial reporting could lead to errors in financial reporting.
• Patent applications do not guarantee patent issuance, breadth, or enforceability.
• The proposed mechanisms for MODS Max have not been established in controlled, independently reproducible human studies.
• Commercial use or formulation stability of MODS Max does not independently establish enhanced absorption or clinical outcomes.
• Competition in the mental health and wellness market is increasing.
• The success of the MODS Max platform depends on independent validation, market acceptance, and potential third-party adoption.
• There can be no assurance that the company will satisfy listing requirements or successfully complete an uplisting to a senior exchange.

Future Outlook

Management is optimistic about carving out profitable positions through patent-pending Methylene Blue products and specialty offerings, targeting markets like dementia, ADHD, Long Covid, and weight loss. The company is focusing on building a cellular-wellness and delivery-technology platform with MODS Max, aiming for both product revenue and potential technology licensing. Several distribution opportunities anticipated for 2026 have been delayed to 2027. Management believes its current cash balance is sufficient for the next year, but acknowledges the need for future capital infusion and is preparing for a potential senior exchange uplisting.

Management Comments

• As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings.
• Management is still confident in reaching the projected year over year growth.
• Management believes that MODS Max, a patent-pending stabilized aqueous mineral-oxide formulation system, represents a principal long-term strategic opportunity.
• Management believes its 2026 development activities have expanded the potential pathways available for pursuing that objective.
• Management believes its current cash balance is sufficient to meet its obligations over the next year.

Industry Context

StockSavvy.ai notes that BioScience Health Innovations operates in the growing health and wellness sector, with a specific focus on mental health and mitochondrial support. The company's strategy around MODS Max and Methylene Blue products aligns with increasing market interest in natural health solutions and addressing conditions like cognitive decline and energy levels. However, the company faces significant competition and the challenge of substantiating its proprietary technology's efficacy through rigorous scientific validation.

Comparison to Industry Standards

• The company's reliance on patent-pending technology without independent validation contrasts with industry standards for pharmaceutical or advanced supplement development, which typically require extensive clinical trials and regulatory approval.
• The reported revenue decline and net losses are concerning when compared to established players in the health and wellness market who often demonstrate consistent revenue growth and profitability.
• The identification of material weaknesses in internal controls is a significant deviation from the robust governance and financial reporting expected of publicly traded companies aiming for senior exchange listings.

Corporate Governance

Related Party Transactions

• During the nine months ended September 30, 2025, the Company received advances of $2,422,096 from Ageless Holdings, LLC (Holdings), an entity owned and controlled by management and board members, for inventory, services, and operating expenses. Repayments of $2,172,000 were made.
• During the nine months ended September 30, 2026, the Company purchased $745,060 worth of inventory from Holdings, received $11,863 in advances for operating expenses, and repaid $150,000 of advances.
• A promissory note for $460,402 was entered into with Holdings on March 28, 2026, with a 7% interest rate, maturing December 31, 2026.
• Subsequent to the quarter, the Company agreed to acquire a 40% ownership interest in a customer relationship platform from Ageless Holdings, LLC, a related party, for 450,000 restricted shares of common stock.

Stakeholder Impact

• Shareholders may experience dilution from future capital raises and potential stock issuances for acquisitions.
• Shareholders may be concerned about the declining revenue, increasing losses, and material weaknesses in internal controls.
• Employees may be impacted by the company's focus on strategic transformation and technology development, potentially affecting near-term sales initiatives.
• Suppliers may be affected by changes in sales channels and the company's operational transitions.
• Creditors may be impacted by the company's liquidity position and reliance on financing activities.

Next Steps

• Continue development and validation of the MODS Max technology platform.
• Pursue independent scientific validation, including chemical characterization, safety assessments, and controlled transport studies.
• Seek arms-length third-party technology agreements and licensing opportunities.
• Address material weaknesses in internal controls by hiring additional accounting personnel and establishing written policies.
• Proceed with the planned acquisition of Vital Core, Inc. and the customer relationship platform.
• Continue efforts towards a potential uplisting to a senior U.S. securities exchange.
• Focus on gaining traction for mental health and general wellness products.

Key Dates

Recommendation

The company shows strategic long-term potential with its MODS Max platform and subsequent acquisition plans, but current financial performance is weak with declining revenues and increasing losses. Material control weaknesses and delayed revenue opportunities warrant caution. A 'hold' recommendation reflects the balance between speculative upside from technology development and the significant risks associated with current financial health and operational execution.

Keywords

BioScience Health Innovations, MODS Max, Methylene Blue, Mitochondrial Health, Wellness Products, Form 10-Q, Quarterly Report, Health Technology